TY - JOUR
T1 - Metabolic signature of 13C-labeled wheat bran consumption related to gut fermentation in humans
T2 - a pilot study
AU - Meiller, Laure
AU - Sauvinet, Valérie
AU - Breyton, Anne Esther
AU - Ranaivo, Harimalala
AU - Machon, Christelle
AU - Mialon, Anne
AU - Meynier, Alexandra
AU - Bischoff, Stephan C.
AU - Walter, Jens
AU - Neyrinck, Audrey M.
AU - Laville, Martine
AU - Delzenne, Nathalie M.
AU - Vinoy, Sophie
AU - Nazare, Julie Anne
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
PY - 2023/9
Y1 - 2023/9
N2 - Purpose: The aim of this pilot study was to analyze concomitantly the kinetics of production of 13C-labeled gut-derived metabolites from 13C-labeled wheat bran in three biological matrices (breath, plasma, stools), in order to assess differential fermentation profiles among subjects. Methods: Six healthy women consumed a controlled breakfast containing 13C-labeled wheat bran biscuits. H2, CH4 and 13CO2, 13CH4 24 h-concentrations in breath were measured, respectively, by gas chromatography (GC) and GC-isotope ratio mass spectrometry (GC-IRMS). Plasma and fecal concentrations of 13C-short-chain fatty acids (linear SCFAs: acetate, propionate, butyrate, valerate; branched SCFAs: isobutyrate, isovalerate) were quantified using GC-combustion-IRMS. Gut microbiota composition was assessed by16S rRNA gene sequencing analysis. Results: H2 and CH4 24 h-kinetics distinguished two groups in terms of fermentation-related gas excretion: high-CH4 producers vs low-CH4 producers (fasting concentrations: 45.3 ± 13.6 ppm vs 6.5 ± 3.6 ppm). Expired 13CH4 was enhanced and prolonged in high-CH4 producers compared to low-CH4 producers. The proportion of plasma and stool 13C-butyrate tended to be higher in low-CH4 producers, and inversely for 13C-acetate. Plasma branched SCFAs revealed different kinetics of apparition compared to linear SCFAs. Conclusion: This pilot study allowed to consider novel procedures for the development of biomarkers revealing dietary fiber-gut microbiota interactions. The non-invasive assessment of exhaled gas following 13C-labeled fibers ingestion enabled to decipher distinct fermentation profiles: high-CH4 producers vs low-CH4 producers. The isotope labeling permits a specific in vivo characterisation of the dietary fiber impact consumption on microbiota metabolite production. Clinical trial registration: The study has been registered under the number NCT03717311 at ClinicalTrials.gov on October 24, 2018.
AB - Purpose: The aim of this pilot study was to analyze concomitantly the kinetics of production of 13C-labeled gut-derived metabolites from 13C-labeled wheat bran in three biological matrices (breath, plasma, stools), in order to assess differential fermentation profiles among subjects. Methods: Six healthy women consumed a controlled breakfast containing 13C-labeled wheat bran biscuits. H2, CH4 and 13CO2, 13CH4 24 h-concentrations in breath were measured, respectively, by gas chromatography (GC) and GC-isotope ratio mass spectrometry (GC-IRMS). Plasma and fecal concentrations of 13C-short-chain fatty acids (linear SCFAs: acetate, propionate, butyrate, valerate; branched SCFAs: isobutyrate, isovalerate) were quantified using GC-combustion-IRMS. Gut microbiota composition was assessed by16S rRNA gene sequencing analysis. Results: H2 and CH4 24 h-kinetics distinguished two groups in terms of fermentation-related gas excretion: high-CH4 producers vs low-CH4 producers (fasting concentrations: 45.3 ± 13.6 ppm vs 6.5 ± 3.6 ppm). Expired 13CH4 was enhanced and prolonged in high-CH4 producers compared to low-CH4 producers. The proportion of plasma and stool 13C-butyrate tended to be higher in low-CH4 producers, and inversely for 13C-acetate. Plasma branched SCFAs revealed different kinetics of apparition compared to linear SCFAs. Conclusion: This pilot study allowed to consider novel procedures for the development of biomarkers revealing dietary fiber-gut microbiota interactions. The non-invasive assessment of exhaled gas following 13C-labeled fibers ingestion enabled to decipher distinct fermentation profiles: high-CH4 producers vs low-CH4 producers. The isotope labeling permits a specific in vivo characterisation of the dietary fiber impact consumption on microbiota metabolite production. Clinical trial registration: The study has been registered under the number NCT03717311 at ClinicalTrials.gov on October 24, 2018.
KW - C-labeled dietary fiber
KW - Branched short-chain fatty acids
KW - Gut microbiota
KW - Methane
KW - Short-chain fatty acids
KW - Stable isotopes
UR - https://www.scopus.com/pages/publications/85160249866
U2 - 10.1007/s00394-023-03161-5
DO - 10.1007/s00394-023-03161-5
M3 - Article
C2 - 37222787
AN - SCOPUS:85160249866
SN - 1436-6207
VL - 62
SP - 2633
EP - 2648
JO - European Journal of Nutrition
JF - European Journal of Nutrition
IS - 6
ER -